Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Risk-Management Assessment of Visible-Residue Limits in Cleaning Validation
A risk-management assessment of visible-residue limits (VRL) in cleaning validation of pharmaceutical formulations was conducted for both pharmaceutical pilot plant and manufacturing facilities. The authors discuss how potential risks were identified, analyzed for probability, considered for seriousness, and controlled through avoidance or mitigation. These opportunities for VRL implementation then were identified for both pilot plant and manufacturing settings.


Pharmaceutical Technology


10. R.J. Forsyth et al. "Correlation of Visible Residue Limits with Swab Results for Cleaning Validation," Pharm. Technol., in-press.

11. European Commission, "Qualification and Validation," EudraLex, Medicinal Products for Human and Veterinary Use: Good Manufacturing Practice, Vol. 4, Annex 15 (European Commission, Brussels, Belgium, July 2001).

12. Pharmaceutical Inspection Cooperation Scheme (PIC/S), Recommendations on Validation Master Plan, Installation and Operational Qualification, Non-Sterile Process Validation, Cleaning Validation, (PIC/S, Geneva, Switzerland, August 2002).

13. Health Canada, Health Products and Food Branch Inspectorate, "Cleaning Validation Guidelines" (Health Canada, Ottawa, Ontario, Canada, June 2002).

14. R. Sharnez, et al., "In Situ Monitoring of Soil Dissolution Dynamics: A Rapid and Simple Method for Determining Worst-Case Soils for Cleaning Validation," PDA J. Pharm. Sci. and Technol. 58 (4), 203-214 (2004).

Richard Forsyth* is an associate director in global clinical GMP quality with Merck & Co., Inc, WP53C-307, West Point, PA 19486, tel. 215.652.7462, fax 215.652.7106,
Jeffrey Hartman** is a validation manager in regulatory and analytical sciences with Merck & Co., Inc., WP97B-120, West Point, PA 19486, tel. 215.652.8101, fax 215.652.3314,
and Vince Van Nostrand is a research chemist in medicinal chemistry with Merck and Co., Inc.

*To whom pilot-plant correspondence should be addressed.

** To whom manufacturing correspondence should be addressed.

Submitted: May 16, 2006. Accepted: June 21, 2006.

Keywords: cleaning, inspection, risk management, validation, visible residue limit, VRL


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here